Lu Lu, Wan Heng, Yin Yi, Feng Wen-Jun, Wang Ming, Zou Yu-Cong, Huang Bo, Wang Dong-Tao, Shi Yin, Zhao Yan, Wei Lian-Bo
Department of Traditional Chinese Medicine, ZhuJiang Hospital, Southern Medical University, Guangzhou, 510280, China.
Int Urol Nephrol. 2014 Jul;46(7):1383-93. doi: 10.1007/s11255-014-0676-3. Epub 2014 Apr 9.
While many previous studies have reported an association between the p.R229Q variant of the NPHS2 gene and focal segmental glomerulosclerosis (FSGS) or steroid-resistant nephrotic syndrome (SRNS), a conclusive relationship has not been defined. In this study, we performed a meta-analysis of the published data to investigate the impact of the p.R229Q polymorphism on FSGS and SRNS patients. Despite significant heterogeneity within some of the comparisons, the results revealed significantly higher risks of SRNS in individuals homozygous for the variant allele (OR 7.411, 95% confidence interval 1.876-29.436, p = 0.004) compared to homozygous non-variant individuals. However, the carrier rate of the p.R229Q variant was not significantly different between SRNS patients and steroid-sensitive nephrotic syndrome patients. No statistically significant differences in the p.R229Q carrier rate were observed between FSGS patients and controls or FSGS patients and patients with different pathology classifications. No notable differences in the p.R229Q carrier rate were found between patients and controls in any group with early-onset disease (onset age < 18). In conclusion, our meta-analysis suggests that for adult-onset disease (onset age > 18), the homozygous variant could be a potential predictor of hereditary nephrotic syndrome and that the p.R229Q allele cannot currently be considered a risk factor for predicting FSGS.
虽然此前许多研究报告了NPHS2基因的p.R229Q变异与局灶节段性肾小球硬化(FSGS)或激素抵抗型肾病综合征(SRNS)之间存在关联,但尚未明确二者的确切关系。在本研究中,我们对已发表的数据进行了荟萃分析,以探究p.R229Q多态性对FSGS和SRNS患者的影响。尽管部分比较存在显著异质性,但结果显示,与纯合非变异个体相比,变异等位基因纯合个体患SRNS的风险显著更高(比值比7.411,95%置信区间1.876 - 29.436,p = 0.004)。然而,SRNS患者与激素敏感型肾病综合征患者之间p.R229Q变异的携带率并无显著差异。FSGS患者与对照组之间,或FSGS患者与不同病理分类的患者之间,p.R229Q携带率均未观察到统计学显著差异。在任何早发型疾病(发病年龄<18岁)组的患者与对照组之间,均未发现p.R229Q携带率有显著差异。总之,我们的荟萃分析表明,对于成人发病型疾病(发病年龄>18岁),纯合变异可能是遗传性肾病综合征的潜在预测指标,且目前p.R229Q等位基因不能被视为预测FSGS的风险因素。